![](https://medcitynews.com/wp-content/uploads/sites/7/2021/07/49107654333_e9d3fe9dba_c.jpg)
CRISPR biotech Caribou Biosciences’ IPO reels in $304M for next-gen cell therapy
Caribou Biosciences’ CRISPR approach to cell therapy sparked strong investor interest, enabling the clinical-stage biotech to upsize its IPO and raise $304 million in the biggest life sciences IPO this week. Absci, Sophia Genetics, and Cytek Biosciences also priced IPOs.